N-Cadherin antibody | 13A9
N-cadherin is expressed by neurons, endothelial cells, muscle cells, and stem cells, and is one of the primary cadherins recruited to the site of neuronal synapse formation. N-cadherin is directly involved in the differentiation of early hematopoietic progenitors, and is commonly expressed by cancer cells, playing a role in transendothelial migration and metastasis, through the up-regulation of the src kinase pathway, and subsequent failure of the intercellular connection between two adjacent endothelial cells.
Mouse anti Human N-cadherin antibody, clone 13A9 studies have demonstrated that expression levels of E-Cadherin and N-Cadherin have a role to play in the invasive properties of breast cancer. Decreased levels of E-cadherin and loss of E-cadherin-mediated adhesion, can result in the transition of a benign epithelial tumor to an invasive tumor, and increase invasiveness, whilst the expression of N-cadherin correlates with motility, invasiveness and tumor metastasis, irrespective of the presence of E-cadherin (Nieman et al. 1999).
Mouse anti Human N-cadherin antibody, clone 13A9 has been shown to be specific for N-cadherin, and does not recognize E-cadherin, M-cadherin or P-cadherin (Knudsen et al. 1995). Immunohistological studies have shown that clone 13A9 can be used as a reliable marker for the differential diagnosis of pleural mesotheliomas and lung adenocarcinomas, when used in conjunction with E-cadherin (Han et al. 1997).
- Target Species
- Species Cross-Reactivity
Target Species Cross Reactivity Rat
- N.B. Antibody reactivity and working conditions may vary between species.
- Product Form
- Purified IgG - liquid
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
- Carrier Free
- Recombinant MBP fusion protein containing the entire cytoplasmic domain of human N-cadherin.
- Approx. Protein Concentrations
- IgG concentration 1.0mg/ml
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- 18 months from date of despatch.
- P19022 Related reagents
- Q9Z1Y3 Related reagents
- Entrez Gene
- CDH2 Related reagents
- Cdh2 Related reagents
- GO Terms
- GO:0005509 calcium ion binding
- GO:0016021 integral to membrane
- GO:0008013 beta-catenin binding
- GO:0016342 catenin complex
- GO:0034329 cell junction assembly
- GO:0034332 adherens junction organization
- GO:0042692 muscle cell differentiation
- GO:0045294 alpha-catenin binding
- GO:0045295 gamma-catenin binding
- GO:0051149 positive regulation of muscle cell differentiation
- GO:0005916 fascia adherens
- GO:0007416 synapse assembly
- GO:0016339 calcium-dependent cell-cell adhesion
- GO:0019901 protein kinase binding
- GO:0031641 regulation of myelination
- GO:0032403 protein complex binding
- GO:0032880 regulation of protein localization
- GO:0035023 regulation of Rho protein signal transduction
- GO:0044456 synapse part
- GO:0050770 regulation of axonogenesis
- GO:0051291 protein heterooligomerization
- For research purposes only
Applications of N-Cadherin antibody
|Application Name||Verified||Min Dilution||Max Dilution|
|Immunohistology - Frozen|
|Immunohistology - Paraffin 1|
- 1 This product requires antigen retrieval using steam heat treatment prior to staining of paraffin sections. Sodium citrate buffer pH 6.0 is recommended for this purpose.
- Western Blotting
- MCA5698 detects a band of approximately 135-140kDa in human HT-1080 and HeLa cell lysates.
Secondary Antibodies Available
Product Specific References
References for N-Cadherin antibody
Wahl, J.K. 3rd et al. (2003) N-cadherin-catenin complexes form prior to cleavage of the proregion and transport to the plasma membrane.
J Biol Chem. 278 (19): 17269-76.
Knudsen, K.A. et al. (1995) Interaction of alpha-actinin with the cadherin/catenin cell-cell adhesion complex via alpha-catenin.
J Cell Biol. 130 (1): 67-77.
Machell, N.H. et al. (2000) Developmental expression and distribution of N- and E-cadherin in the rat ovary.
Biol Reprod. 63 (3): 797-804.
Han, A.C. et al. (1997) Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues.
Hum Pathol. 28 (6): 641-5.
Peralta Soler, A. et al. (1995) The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas.
Hum Pathol. 26 (12): 1363-9.
Van Aken, E.H. et al. (2002) Structure and function of the N-cadherin/catenin complex in retinoblastoma.
Invest Ophthalmol Vis Sci. 43 (3): 595-602.
Shintani, Y. et al. (2006) Phosphoinositide-3 kinase-Rac1-c-Jun NH2-terminal kinase signaling mediates collagen I-induced cell scattering and up-regulation of N-cadherin expression in mouse mammary epithelial cells.
Mol Biol Cell. 17: 2963-75.
Sacco, P.A. et al. (1995) Identification of plakoglobin domains required for association with N-cadherin and alpha-catenin.
J Biol Chem. 270: 20201-6.
Tian, G. et al. (2009) Clarin-1, encoded by the Usher Syndrome III causative gene, forms a membranous microdomain: possible role of clarin-1 in organizing the actin cytoskeleton.
J Biol Chem. 284: 18980-93.
Theisen, C.S. et al. (2007) NHERF links the N-cadherin/catenin complex to the platelet-derived growth factor receptor to modulate the actin cytoskeleton and regulate cell motility.
Mol Biol Cell. 18: 1220-32.
Nieman, M.T. et al. (1999) N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression.
J Cell Biol. 147 (3): 631-44.
Islam, S. et al. (1996) Expression of N-cadherin by human squamous carcinoma cells induces a scattered fibroblastic phenotype with disrupted cell-cell adhesion.
J Cell Biol. 135 (6 Pt 1): 1643-54.
Peralta Soler, A. et al. (1999) P-cadherin expression in breast carcinoma indicates poor survival.
Cancer. 86: 1263-72.